Inventor · disambiguated record
Chang-Ho Ahn
Also filed as: AHN CHANG H · AHN CHANG HO
17 granted patents·4 pending applications·63 citations·filing 2003–2025
91Inventor score
Top patents by PatentIndex Score
21 records- 0189US8846110B2Polymeric systems for the delivery of anticancer drugsLEE YOUNG B·Filed 2010·Granted Sep 30, 2014·10 cites·20 claims
- 0287US7405214B2Nucleoside derivatives and therapeutic use thereofREXAHN CORP·Filed 2005·Granted Jul 29, 2008·14 cites·18 claims
- 0381US8314100B21-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivativesGONG YOUNG-DAE·Filed 2005·Granted Nov 20, 2012·9 cites·12 claims
- 0480US8598173B21-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumorsKOREA RES INST CHEM TECH·Filed 2012·Granted Dec 3, 2013·5 cites·20 claims
- 0579US10307490B2Lipid nanoparticle compositions for antisense oligonucleotides deliveryUNIV OHIO STATE·Filed 2013·Granted Jun 4, 2019·1 cites·32 claims
- 0673US8034829B25, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereofREXAHN PHARMACEUTICALS INC·Filed 2007·Granted Oct 11, 2011·2 cites·18 claims
- 0773US7122527B2Use of antisense oligonucleotides to inhibit the expression of human Akt-1REXAHN CORP·Filed 2003·Granted Oct 17, 2006·12 cites·20 claims
- 0872US7205283B2Antisense oligonucleotides that inhibit expression of HIF-1REXAHN CORP·Filed 2004·Granted Apr 17, 2007·9 cites·5 claims
- 0971US8404698B2Quinazoline derivatives and therapeutic use thereofLEE YOUNG BOK·Filed 2008·Granted Mar 26, 2013·1 cites·13 claims
- 1065US9434610B2HPMA—docetaxel conjugates and uses thereforeLEE YOUNG B·Filed 2009·Granted Sep 6, 2016·0 cites·19 claims
- 1163US2015071872A1Polymeric systems for the delivery of anticancer drugsREXAHN PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1261US9193707B2Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compoundsLEE YOUNG BOK·Filed 2014·Granted Nov 24, 2015·0 cites·20 claims
- 1359US2009270358A1Pharmaceutical formulation of clavulanic acidREXAHN PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1456US9744167B2Nanoparticulate compositions and formulations of piperazine compoundsREXAHN PHARMACEUTICALS INC·Filed 2014·Granted Aug 29, 2017·0 cites·19 claims
- 1553US10696548B2Method of preparing a single-phase oxide for hydrogen storage having a TiO2 crystal phaseKOREA RES INST STANDARDS & SCI·Filed 2018·Granted Jun 30, 2020·0 cites·10 claims
- 1653US9713615B2Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compoundsREXAHN PHARMACEUTICALS INC·Filed 2015·Granted Jul 25, 2017·0 cites·21 claims
- 1752US10052321B2Nanoparticulate compositions and formulations of piperazine compoundsREXAHN PHARMACEUTICALS INC·Filed 2017·Granted Aug 21, 2018·0 cites·23 claims
- 1852US2025252760A1Method and apparatus for analyzing pathological slide imagesLUNIT INC·Filed 2025·Application pending·0 cites
- 1950US7388014B2Quinazoline derivatives and therapeutic use thereofREXAHN PHARMACEUTICALS INC·Filed 2005·Granted Jun 17, 2008·0 cites·19 claims
- 2045US8314123B25, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereofLEE YOUNG BOK·Filed 2011·Granted Nov 20, 2012·0 cites·16 claims
- 2134US2010255099A1Clavulanate formulation for neuroprotection and treatment of neurodegenerative disordersREXAHN PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chang-Ho Ahn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →